Trial · NCT00988247
Adverse events38
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 38
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nasopharyngitis | Infections and infestations | BDP HFA 320 µg/Day | 67 | 415 | |
| other | Nasopharyngitis | Infections and infestations | Placebo | 14 | 111 | |
| other | Sinusitis | Infections and infestations | BDP HFA 320 µg/Day | 34 | 415 | |
| other | Sinusitis | Infections and infestations | Placebo | 8 | 111 | |
| other | Upper respiratory tract infection | Infections and infestations | BDP HFA 320 µg/Day | 43 | 415 | |
| other | Upper respiratory tract infection | Infections and infestations | Placebo | 7 | 111 | |
| other | Headache | Nervous system disorders | BDP HFA 320 µg/Day | 28 | 415 | |
| other | Headache | Nervous system disorders | Placebo | 6 | 111 | |
| other | Epistaxis | Respiratory, thoracic and mediastinal disorders | BDP HFA 320 µg/Day | 44 | 415 | |
| other | Epistaxis | Respiratory, thoracic and mediastinal disorders | Placebo | 2 | 111 | |
| serious | Nephrolithiasis | Renal and urinary disorders | BDP HFA 320 µg/Day | 1 | 415 | |
| serious | Nephrolithiasis | Renal and urinary disorders | Placebo | 0 | 111 | |
| serious | Intraocular pressure increased | Investigations | BDP HFA 320 µg/Day | 1 | 415 | |
| serious | Intraocular pressure increased | Investigations | Placebo | 0 | 111 | |
| serious | Colon cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | BDP HFA 320 µg/Day | 2 | 415 | |
| serious | Colon cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Placebo | 0 | 111 | |
| serious | Bladder injury | Injury, poisoning and procedural complications | BDP HFA 320 µg/Day | 1 | 415 | |
| serious | Bladder injury | Injury, poisoning and procedural complications | Placebo | 0 | 111 | |
| serious | Menorrhagia | Reproductive system and breast disorders | BDP HFA 320 µg/Day | 1 | 415 | |
| serious | Menorrhagia | Reproductive system and breast disorders | Placebo | 0 | 111 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00988247/events